- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00676676
Effects of Testosterone in Women With Depression
Effects of Testosterone in Women With Depression: A Pilot Study
The purpose of the study is to determine whether adding a low dose of testosterone to current antidepressant therapy improves depression and fatigue in women who remain depressed despite necessary adequate doses of anti-depressants. Testosterone will be given over an 8-week period.
Testosterone is a hormone that occurs naturally in the body. In women it comes from the ovaries and adrenal glands and is found in amounts that are ten to twenty times lower than in men.
In early research studies, testosterone has been shown to have some antidepressant effects in the following groups of subjects:
- Women with anorexia nervosa
- Women who have low testosterone levels because their pituitary glands do not work
- Men with Selective Serotonin Reuptake Inhibitor (SSRI)-resistant depression.
However, testosterone administration in women with SSRI or Serotonin-norepinephrine reuptake inhibitor (SNRI) -resistant depression has not been studied.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female, age 18-75
- Written informed consent
- Meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (by Structured Clinical Interview for DSM-IV (SCID)) for Major Depressive Disorder
- Meet DSM-IV criteria for a current major depressive episode, as assessed by SCID
- Montgomery-Asberg Depression Rating Scale (MADRS) greater than or equal to 16 at baseline visit
- Currently treated with SSRI or SNRI, with or without adjunctive therapy, at an adequate dose (see adequate dose table below) for at least six weeks
Exclusion Criteria:
- Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
- Serious suicide or homicide risk, as assessed by evaluating clinician
- Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic (including uncontrolled seizure disorder)
- Substance use disorder active within last six months
- Psychotic features (current episode or lifetime), as assessed by SCID
- Laboratory evidence of untreated hypothyroidism
- If treated hypothyroidism, significant change in levo-thyroxine dose within the prior three months
- If receiving oral estrogen therapy, including oral contraceptives or transdermal estrogen therapy, significant change in dose in the prior three months
- Use of androgens or androgen precursors, including testosterone, Dehydroepiandrosterone (DHEA) and methyltestosterone, within the prior three months
- Any investigational psychotropic drug within the last two weeks
- In the judgment of the study clinician, unlikely to be able to participate safely throughout the study period (three or more episodes of self-harm in the past year, documented history of poor treatment adherence, or frequent missed appointments (greater than 50%) in the past year)
- Alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal.
- Creatinine greater than 1.5 times upper limit of normal
- History of a hormone-responsive cancer
- History of congestive heart failure
- MADRS greater than 31
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Testosterone
Testosterone patch delivering 300mcg daily for 8-weeks.
|
Testosterone atch delivering 300mcg daily for 8-weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Montgomery-Asberg Depression Rating Scale (MADRS) Scale
Time Frame: Baseline, 2-week, 8-week
|
the MADRS is a diagnostic questionnaire that is used to measure the severity of depressive episodes in patients with mood disorders.
The minimum and maximum values are 0 and 60 respectively (higher scores are more severe).
|
Baseline, 2-week, 8-week
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Karen K Miller, MD, Massachsuetts General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007p000348
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Testosterone
-
University of VermontSuspendedBreast Neoplasms | Vaginitis | DyspareuniaUnited States
-
University of PennsylvaniaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedHypogonadism | Growth Hormone Deficiency | HypopituitarismUnited States
-
Men's Health BostonCompletedHypogonadism, Male | Testosterone DeficiencyUnited States
-
VA Office of Research and DevelopmentHunter Holmes McGuire VA Medical CenterCompleted
-
Leonard S. Marks, M.D.Watson Pharmaceuticals; Solvay PharmaceuticalsCompletedMen With Low Testosterone LevelsUnited States
-
Charles Drew University of Medicine and ScienceCompletedStress Urinary IncontinenceUnited States
-
Yale UniversityDendreonRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
American Hip InstituteWithdrawnArthroplasty, Replacement, HipUnited States
-
VA Office of Research and DevelopmentVirginia Commonwealth UniversityCompleted
-
Biolab Sanus FarmaceuticaWithdrawnPost-menopausal Period